Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03075865 · ClinicalTrials.gov registry record
A Cohort Study for Clinical Evaluation of OmniMax MMF System
A clinical trial, sponsored by Zimmer Biomet.
- Completed
- Registry status
- 39
- Enrollment target
NCT03075865: Completed study, sponsored by Zimmer Biomet.
NCT03075865 is a clinical trial that has completed, run by Zimmer Biomet. The registered enrollment target is 39 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03075865 has completed, sponsored by Zimmer Biomet.
- COMPLETED
- Registry status
- 39 participants
- Enrollment target
Study Summary
OmniMax MMF system was designed as a device with faster application/removal time, less mucosal tissue overgrowth over the plates and screws, better tolerance for placement over prolong periods of time, better patient hygiene and a lower risk for further treatments secondary to root damage from the insertion of the screws, compared to the standard of care for maxillo-mandibular fixation and other hybrid systems. This clinical trial intends to highlight the clinical benefits of the OmniMax MMF system applied to patients undergoing repair of uncomplicated mandibular fracture(s) for whom OmniMax MMF system is used as a single mean for maxillo-mandibular fixation.
Primary Outcome
Dental root damage can be caused from insertion of the screws at time of implantation. Some of these events may require further medical or surgical treatment
Interventions
- DEVICE OmniMax MMF system
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2017-06-28 |
| Est. Completion | 2019-06-28 |
What the finished NCT03075865 record still lists
NCT03075865 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 39 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which OmniMax MMF system is the first listed.
NCT03075865 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03075865 about?
NCT03075865 is a clinical study titled "A Cohort Study for Clinical Evaluation of OmniMax MMF System". OmniMax MMF system was designed as a device with faster application/removal time, less mucosal tissue overgrowth over the plates and screws, better tolerance for placement over prolong periods of time, better patient hygiene and a lower risk for further treatments secondary to root damage from the i...
What is the current status of trial NCT03075865?
This trial is currently completed. The enrollment target is 39 participants. The study started on 2017-06-28. Estimated completion is 2019-06-28.
What interventions are being tested in trial NCT03075865?
The interventions under investigation include: OmniMax MMF system (DEVICE).
Who is sponsoring clinical trial NCT03075865?
This trial is sponsored by Zimmer Biomet, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI